← Company directoryNASDAQ · SEC EDGAR
Agios Pharmaceuticals, Inc.
AGIOA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
Agios Q3 2026 results call
Agios management will report third-quarter 2026 financial results and business highlights during its November 5 call at 8:00 AM EST, equivalent to 4:00 PM in Istanbul after the U.S. daylight-saving transition. The company did not announce a separate results-release minute.
Agios ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
AFRMAffirm Holdings, Inc.NASDAQ · SEC→AFYAAfya Limited - Class A Common SharesNASDAQ · SEC→AGCCAgencia Comercial Spirits Ltd - Class A Ordinary ShareNASDAQ · SEC→AGENAgenus Inc.NASDAQ · SEC→AGMBAgomAb Therapeutics NV - ADRs representing one common share.NASDAQ · SEC→AGMHAGM Group Holdings Inc. - Class A Ordinary SharesNASDAQ · SEC→AGNCAGNC Investment Corp.NASDAQ · SEC→AGNCLAGNC Investment Corp.NASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.